Auro-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91672 · Verify on the e-Formulary ↗ (DIN 02432242)
Source record
DIN 02432242: Auro-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id AUR
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02432242
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91672Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2025-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02432242
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Moxifloxacin · DIN 02443929 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Moxifloxacin · DIN 02443929
Manufacturer: Jamp Pharma Corporation; listing date 2015-12-22
Health Canada: Marketed since 2025-10-31 · brand JAMP-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92870 · Verify on the e-Formulary ↗ (DIN 02443929)
Source record
DIN 02443929: Jamp-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id JPC
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443929
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92870Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2025-10-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02443929
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Moxifloxacin · DIN 02472791 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Moxifloxacin · DIN 02472791
Manufacturer: Mantra Pharma Inc.; listing date 2019-03-28
Health Canada: Marketed since 2024-01-10 · brand M-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Mantra pharma inc · schedule Prescription
M-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96210 · Verify on the e-Formulary ↗ (DIN 02472791)
Source record
DIN 02472791: M-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id MAT
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472791
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96210Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2025-05-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472791
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Moxifloxacin · DIN 02520710 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Moxifloxacin · DIN 02520710
Manufacturer: Sanis Health Inc.; listing date 2022-06-30
Health Canada: Marketed since 2022-04-04 · brand MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Sanis health inc · schedule Prescription
Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100991 · Verify on the e-Formulary ↗ (DIN 02520710)
Source record
DIN 02520710: Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id SAI
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520710
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100991Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2025-08-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02520710
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Moxifloxacin · DIN 02383381 · 400mg · tablet
General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Moxifloxacin · DIN 02383381
Manufacturer: Sandoz Canada Inc.; listing date 2018-01-31
Health Canada: Marketed since 2017-11-30 · brand SANDOZ MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86914 · Verify on the e-Formulary ↗ (DIN 02383381)
Source record
DIN 02383381: Sandoz Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id SDZ
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02383381
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86914Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2026-04-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02383381
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Moxifloxacin · DIN 02375702 · 400mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Moxifloxacin · DIN 02375702
Manufacturer: Teva Canada Limited; listing date 2016-01-28
Health Canada: Marketed since 2015-11-04 · brand TEVA-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Teva canada limited · schedule Prescription
Teva-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86112 · Verify on the e-Formulary ↗ (DIN 02375702)
Source record
DIN 02375702: Teva-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id TEV
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375702
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86112Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375702
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Moxifloxacin · DIN 02406373
Manufacturer: Apotex Inc.; listing date 2016-01-28
Health Canada: Marketed since 2015-11-19 · brand APO-MOXIFLOXACIN · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 %/W/V · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89109 · Verify on the e-Formulary ↗ (DIN 02406373)
Source record
DIN 02406373: Apo-Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id APX
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406373
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89109Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Act Moxifloxacin · DIN 02404656 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: active shortage (reported 2025-12-02, estimated to end 2026-10-30, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406373
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Moxifloxacin · DIN 02529076
Manufacturer: Sanis Health Inc.; listing date 2023-01-31
Health Canada: Marketed since 2022-12-21 · brand MOXIFLOXACIN · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 %/W/V · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101826 · Verify on the e-Formulary ↗ (DIN 02529076)
Source record
DIN 02529076: Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id SAI
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529076
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101826Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Act Moxifloxacin · DIN 02404656 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: active shortage (reported 2026-08-05, estimated to end 2026-09-25, last updated 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529076
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91667 · Verify on the e-Formulary ↗ (DIN 02432218)
Source record
DIN 02432218: PMS-Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id PMS
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2701; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02432218
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91667Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Act Moxifloxacin · DIN 02404656 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: resolved shortage (ended 2024-09-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02432218
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Moxifloxacin · DIN 02411520
Manufacturer: Sandoz Canada Inc.; listing date 2015-12-22
Health Canada: Marketed since 2015-10-29 · brand SANDOZ MOXIFLOXACIN · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 % · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89614 · Verify on the e-Formulary ↗ (DIN 02411520)
Source record
DIN 02411520: Sandoz Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id SDZ
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411520
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89614Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Act Moxifloxacin · DIN 02404656 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: resolved shortage (ended 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411520
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Vigamox · DIN 02252260
Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-12-22
Health Canada: Marketed since 2018-03-15 · brand VIGAMOX · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 % · company Novartis pharmaceuticals canada inc · schedule Prescription
Vigamox: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73714 · Verify on the e-Formulary ↗ (DIN 02252260)
Source record
DIN 02252260: Vigamox
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id NOV
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02252260
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73714Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Act Moxifloxacin · DIN 02404656 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Shortage status: resolved shortage (ended 2019-03-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02252260
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96886 · Verify on the e-Formulary ↗ (DIN 02478137)
Source record
DIN 02478137: AG-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id ANG
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478137
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96886Interchangeable products
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02478137
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-07-26 — choose a marketed DIN from the same-category list.
Apo-Moxifloxacin · DIN 02404923 · 400mg · tablet
General benefitDormant since 2026-04-08 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Moxifloxacin · DIN 02404923
Manufacturer: Apotex Inc.; listing date 2016-03-30
Health Canada: Dormant since 2026-04-08 · brand APO-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Apotex inc · schedule Prescription
Apo-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88976 · Verify on the e-Formulary ↗ (DIN 02404923)
Source record
DIN 02404923: Apo-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id APX
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404923
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88976Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: active shortage (reported 2025-03-18, last updated 2025-05-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02404923
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-04-08 — choose a marketed DIN from the same-category list.
Jamp-Moxifloxacin Tablets · DIN 02447061 · 400mg · tablet
General benefitDormant since 2019-08-05 · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Moxifloxacin Tablets · DIN 02447061
Manufacturer: Jamp Pharma Corporation; listing date 2016-03-30
Health Canada: Dormant since 2019-08-05 · brand JAMP-MOXIFLOXACIN TABLETS · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Moxifloxacin Tablets: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93264 · Verify on the e-Formulary ↗ (DIN 02447061)
Source record
DIN 02447061: Jamp-Moxifloxacin Tablets
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id JPC
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447061
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93264Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02447061
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2019-08-05 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-07-30 · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Moxifloxacin · DIN 02484757
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Dormant since 2025-07-30 · brand AG-MOXIFLOXACIN · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 %/W/V · company Angita pharma inc. · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97504 · Verify on the e-Formulary ↗ (DIN 02484757)
Source record
DIN 02484757: AG-Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id ANG
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484757
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97504Interchangeable products
Act Moxifloxacin · DIN 02404656 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02484757
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-30 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-07-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Moxifloxacin · DIN 02472120
Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30
Health Canada: Dormant since 2025-07-31 · brand JAMP-MOXIFLOXACIN · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 %/W/V · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96141 · Verify on the e-Formulary ↗ (DIN 02472120)
Source record
DIN 02472120: Jamp-Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id JPC
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472120
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96141Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Act Moxifloxacin · DIN 02404656 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-09-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472120
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.
Med-Moxifloxacin · DIN 02457814 · 400mg · tablet
General benefitApproved · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Med-Moxifloxacin · DIN 02457814
Manufacturer: Generic Medical Partners Inc.; listing date 2017-02-28
Health Canada: Approved since 2016-12-12 · brand MED-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Generic medical partners inc · schedule Prescription
Med-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94484 · Verify on the e-Formulary ↗ (DIN 02457814)
Source record
DIN 02457814: Med-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id GMP
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457814
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94484Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457814
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Approved since 2016-12-12 — choose a marketed DIN from the same-category list.
Mar-Moxifloxacin · DIN 02447053 · 400mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-18 — choose a marketed DIN from the same-category list.Discontinued 2026-03-18 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-03-18 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-03-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Moxifloxacin · DIN 02447053
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2016-01-28
Health Canada: Cancelled post market since 2026-03-18 · brand MAR-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.5230 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93263 · Verify on the e-Formulary ↗ (DIN 02447053)
Source record
DIN 02447053: Mar-Moxifloxacin
Raw flags: sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id MAR
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $1.5230; ministry $1.5230
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447053
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93263Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Avelox · DIN 02242965 · not recorded
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2019-01-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02447053
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-03-18 — choose a marketed DIN from the same-category list.
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-27 — choose a marketed DIN from the same-category list.Discontinued 2022-05-27 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-05-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Moxifloxacin · DIN 02404656
Manufacturer: Actavis Pharma Company; listing date 2015-12-22
Health Canada: Cancelled post market since 2022-05-27 · brand ACT MOXIFLOXACIN · ATC S01AE07 MOXIFLOXACIN · form Solution · route Ophthalmic · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 0.5 %/W/V · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88945 · Verify on the e-Formulary ↗ (DIN 02404656)
Source record
DIN 02404656: Act Moxifloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520404048; group id 581; item number 1536; lccId None; manufacturer id ACV
Source form: Oph Sol-3mL Pk (Preservative-Free); strength: 0.5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $11.2700; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404656
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88945Interchangeable products
AG-Moxifloxacin · DIN 02484757 · not recorded
Apo-Moxifloxacin · DIN 02406373 · not recorded
Jamp-Moxifloxacin · DIN 02472120 · not recorded
Moxifloxacin · DIN 02529076 · not recorded
PMS-Moxifloxacin · DIN 02432218 · not recorded
Sandoz Moxifloxacin · DIN 02411520 · not recorded
Vigamox · DIN 02252260 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02404656
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-05-27 — choose a marketed DIN from the same-category list.
Avelox · DIN 02242965 · 400mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.Discontinued 2019-07-04 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Avelox · DIN 02242965
Manufacturer: Bayer Inc., Consumer Care Division; listing date 2001-06-07
Health Canada: Cancelled post market since 2019-07-04 · brand AVELOX · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Bayer inc · schedule Prescription
Avelox: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66804 · Verify on the e-Formulary ↗ (DIN 02242965)
Source record
DIN 02242965: Avelox
Raw flags: notABenefit=Y, sec3=Y
Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id BAY
Source form: Tab; strength: 400mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242965
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66804Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230
Apo-Moxifloxacin · DIN 02404923 · $1.5230
Auro-Moxifloxacin · DIN 02432242 · $1.5230
Jamp-Moxifloxacin · DIN 02443929 · $1.5230
Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230
M-Moxifloxacin · DIN 02472791 · $1.5230
Mar-Moxifloxacin · DIN 02447053 · $1.5230
Med-Moxifloxacin · DIN 02457814 · $1.5230
Moxifloxacin · DIN 02520710 · $1.5230
Sandoz Moxifloxacin · DIN 02383381 · $1.5230
Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: discontinued (2019-07-04, reported by BAYER INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242965
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-07-04 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM
08:40 Miscellaneous Anti-Infectives
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered
Matched class: 52:04:04 Antibiotics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE
52:04:04 Antibiotics
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
GATIFLOXACIN · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
ZYMAR® (gatifloxacin) is indicated for the treatment of patients 1 year of age and older with bacterial
conjunctivitis caused by susceptible strains of the following bacteria:
Aerobic Gram-positive bacteria:
• Staphylococcus aureus
• Staphylococcus epidermidis
• Streptococcus pneumoniae
Aerobic Gram-negative bacteria:
• Haemophilus influenzae
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYMAR and
other antibacterial drugs, ZYMAR should be used only to treat infections that are proven or strongly
suspected to be caused by susceptible bacteria.
1.1 Pediatrics
Pediatrics (≥ 1 year and ≤ 12 years of age): Based on the data submitted and reviewed by Health
Canada, the safety and efficacy of ZYMAR in pediatric patients 1 year of age and older has been
established; therefore, Health Canada has authorized an indication for pediatric use.
PM: https://pdf.hres.ca/dpd_pm/00067074.PDF; date AUG 30, 2004; DIN 02257270; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
VIGAMOX® (moxifloxacin ophthalmic solution) is indicated for the treatment of patients 1 year
of age and older with bacterial conjunctivitis caused by susceptible strains of the following
organisms:
Aerobic, Gram-Positive
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus haemolyticus
Staphylococcus hominis
Streptococcus pneumoniae
Streptococcus viridans group
Aerobic, Gram-Negative
Acinetobacter species
Haemophilus influenza
To reduce the development of the drug-resistant bacteria and maintain the effectiveness of
VIGAMOX and other antibacterial drugs, VIGAMOX should be used only to treat infections
that are proven or strongly suspected to be caused by susceptible bacteria. When culture and
susceptibility information are available, they should be considered in selecting or modifying
antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns
may contribute to the empiric selection of therapy.
VIGAMOX® Product Monograph Page 3 of 27
Geriatrics (> 65 years of age):
No overall differences in safety and effectiveness have been observed …
https://pdf.hres.ca/dpd_pm/00042774.PDF
PM date: December 1, 2017
Source product: VIGAMOX; DIN 02252260; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Teva-Moxifloxacin · DIN 02375702
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375702
Apo-Moxifloxacin · DIN 02406373
Shortage status: active shortage (reported 2025-12-02, estimated to end 2026-10-30, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406373
Moxifloxacin · DIN 02529076
Shortage status: active shortage (reported 2026-08-05, estimated to end 2026-09-25, last updated 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529076
Apo-Moxifloxacin · DIN 02404923
Shortage status: active shortage (reported 2025-03-18, last updated 2025-05-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02404923
Jamp-Moxifloxacin · DIN 02472120
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-09-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472120
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Apo-Moxifloxacin, Moxifloxacin, PMS-Moxifloxacin, Sandoz Moxifloxacin, Vigamox, AG-Moxifloxacin, Jamp-Moxifloxacin, Act Moxifloxacin, Avelox: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.